Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,011.12 -11.09 (-0.22%) Dow
37,775.38 +22.07 (+0.06%) Nasdaq
15,601.50 -81.87 (-0.52%) Bitcoin USD
63,001.36 +1,827.68 (+2.99%) CMC Crypto 200
1,302.00 +416.46 (+46.53%)
Eloxx Pharmaceuticals, Inc. (ELOX)
| Previous close | 0.9625 |
| Open | 0.9500 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's range | 0.9400 - 0.9800 |
| 52-week range | 0.4000 - 10.9000 |
| Volume | |
| Avg. volume | 9,313 |
| Market cap | 2.955M |
| Beta (5Y monthly) | 2.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.8800 |
| Earnings date | 18 Apr 2024 - 21 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.00 |
GlobeNewswireEloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (A
- GlobeNewswire
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) BARCELONA, Spain and W
- GlobeNewswire
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ELX-02 improved podocyte foot process effacement in all three treated patients by an average of 60% based on blinded biopsy analysis by NIPOKA GmbH Clinical data from Phase 2 study of ELX-02 for Alport Syndrome included in presentations at the American Society of Nephrology (ASN) Kidney Week 2023 Sig
